Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462808 | 0.84 | FFAR1 (0.50) | LDHAPOLBFFAR1MMP1MMP2 | |
| SCHEMBL11221835 | 0.83 | LDHA (0.66) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL6177062 | 0.81 | LDHA (0.64) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL6462909 | 0.81 | LDHA (0.64) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL6462666 | 0.81 | KMT2A (0.48) | FFAR1PPARGPPARA | |
| SCHEMBL6467779 | 0.80 | LDHA (0.62) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL6461540 | 0.80 | LDHA (0.62) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL6178867 | 0.80 | LDHA (0.67) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL5748284 | 0.79 | LDHA (0.71) | LDHAPOLBFFAR1PPARGPPARA | |
| SCHEMBL6177637 | 0.79 | LDHA (0.60) | LDHAPOLBPPARGPPARAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903233-B2 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1344763-A1 | Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters | Takasago International Corporation (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | HDHD5, APEH, AOC3 | LDHA 3066/4885POLB 2554/4885FFAR1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.